Lalau: Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19

Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19

Lalau et al., Diabetes & Metabolism, doi:10.1016/j.diabet.2020.101216

Lalau et al., Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for.., Diabetes & Metabolism, doi:10.1016/j.diabet.2020.101216

Dec 2020 Source PDF

Twitter
Facebook

All Studies Meta

Retrospective 2,449 hospitalized COVID-19 diabetes patients in France, 1,496 with existing metformin use, showing lower mortality with treatment. Statistical significance was reached in model 1 but not in models 2-4 which also adjust for HbA1c, eGFR, and diabetes duration, but have a lower number of patients. CORONADO (Coronavirus SARS-CoV-2 and Diabetes Outcomes).

Although the 22% lower mortality is not statistically significant, it is consistent with the significant 32% lower mortality [27‑37%] from meta analysis of the 46 mortality results to date.

Important missing comments or errors? Let us know.

risk of death, 22.2% lower, OR 0.78, p = 0.16, treatment 671, control 419, day 28, model 2, propensity score matching, RR approximated with OR.

risk of death/intubation, 17.8% lower, OR 0.82, p = 0.21, treatment 671, control 419, day 28, model 2, propensity score matching, primary outcome, RR approximated with OR.

risk of mechanical ventilation, 6.8% lower, OR 0.93, p = 0.72, treatment 671, control 419, day 28, model 2, propensity score matching, RR approximated with OR.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Lalau et al., 10 Dec 2020, retrospective, France, peer-reviewed, 33 authors, study period 10 March, 2020 - 10 April, 2020.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Metformin All

Abstract: Diabetes & Metabolism 47 (2021) 101216 Available online at ScienceDirect www.sciencedirect.com Original article Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19 Jean-Daniel Lalau a,b,*, Abdallah Al-Salameh a,b,*, Samy Hadjadj c, Thomas Goronﬂot d, Nicolas Wiernsperger e, Matthieu Pichelin c, Ingrid Allix f, Coralie Amadou g, Olivier Bourron h, Thierry Duriez i, Jean-François Gautier j, Anne Dutour k, Céline Gonfroy l, Didier Gouet m, Michael Joubert n, Ingrid Julier o, Etienne Larger p, Lucien Marchand q, Michel Marre r, Laurent Meyer s, Frédérique Olivier t, Gaëtan Prevost u, Pascale Quiniou v, Christelle Raffaitin-Cardin w, Ronan Roussel x, Pierre-Jean Saulnier y , Dominique Seret-Begue z, Charles Thivolet aa, Camille Vatier bb, Rachel Desailloud a,b, Matthieu Wargny d, Pierre Gourdy cc,1, Bertrand Cariou c,1 for the CORONADO investigators2 a Department of Endocrinology, Diabetes Mellitus and Nutrition, Amiens University Hospital, 80054 Amiens, France PériTox = UMR_I 01, University of Picardie Jules Verne, Amiens, France Département d’Endocrinologie, Diabétologie et Nutrition, l’institut du Thorax, Inserm, CNRS, UNIV Nantes, CHU Nantes, Hôpital Guillaume et René Laennec, 44093 Nantes Cedex 01, France d Data Clinic, INSERM, CIC 1413, PHU 11, Nantes University Hospital, Nantes, France e Association REMEDES, Ville-sur-Jarnioux, France f Département d’Endocrinologie, Diabétologie, Nutrition, CHU Angers, Angers, France g Département de Diabétologie, Centre Hospitalier Sud Francilien, Corbeil Essonne, France h Sorbonne Université, Assistance Publique Hôpitaux de Paris, Département de Diabétologie, CHU La Pitié Salpêtrière-Charles Foix, Inserm, UMR_S 1138, Centre de Recherche des Cordeliers, Paris 06, Institute of Cardiometabolism and Nutrition ICAN, Paris, France i Service D’Endocrinologie, Diabétologie, CH Cholet, Cholet, France j Département Diabète et Endocrinologie, Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris, Paris, France k Département d’Endocrinologie et de Diabétologie, Hôpital Nord, Assistance Publique Hôpitaux de Marseille, Marseille, France l Service d’Endocrinologie, Diabétologie, CH de Pontoise, Pontoise, France m Service de Diabétologie, Endocrinologie, Centre Hospitalier de la Rochelle, La Rochelle, France n Service Diabétologie-endocrinologie, CHU Caen, Caen, France o CH de Ales, Ales, France p Université de Paris and AP-HP, Centre Hospitalier Universitaire de Paris, Cochin Hospital, Paris, France q Département d’Endocrinologie et de Diabétologie, Centre Hospitalier St. Joseph - St. Luc, Lyon, France r Clinique Ambroise Paré Neuilly-sur-Seine, Centre de Recherches des Cordelier, Université Paris Diderot, Paris, France s Service d’Endocrinologie, Diabète et Nutrition, HUS - Hôpital Civil, Strasbourg, France t Service de Diabétologie, Centre Hospitalier de Cahors, Cahors, France u Département d’Endocrinologie, Diabétologie et Maladies Métaboliques, CHU de Rouen, Université de Rouen, Rouen, France v CHU de Brest, Brest, France w CH Robet Boulin de Libourne, Libourne, France x Département d’Endocrinologie, Diabétologie et Nutrition, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Centre de Recherche des Cordeliers, Inserm, U-1138, Université de Paris, Paris, France y Centre d’Investigation Clinique CIC 1402, Université de Poitiers, Inserm, CHU de Poitiers, Poitiers, France z Service de..

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit